ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
19.85
-0.26 (-1.29%)
At close: Dec 5, 2025, 4:00 PM EST
19.69
-0.16 (-0.80%)
After-hours: Dec 5, 2025, 7:10 PM EST
ADMA Biologics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 28.5, with a low estimate of 25 and a high estimate of 32. The average target predicts an increase of 43.58% from the current stock price of 19.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 8, 2025.
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $25 → $32 | Strong Buy | Maintains | $25 → $32 | +61.21% | May 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +25.94% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +30.98% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +25.94% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -9.32% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
521.08M
from 426.45M
Increased by 22.19%
Revenue Next Year
647.87M
from 521.08M
Increased by 24.33%
EPS This Year
0.60
from 0.81
Decreased by -26.12%
EPS Next Year
0.93
from 0.60
Increased by 55.68%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 536.9M | 673.6M | ||||
| Avg | 521.1M | 647.9M | ||||
| Low | 500.2M | 618.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 25.9% | 29.3% | ||||
| Avg | 22.2% | 24.3% | ||||
| Low | 17.3% | 18.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.63 | 1.03 | ||||
| Avg | 0.60 | 0.93 | ||||
| Low | 0.56 | 0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -22.2% | 72.0% | ||||
| Avg | -26.1% | 55.7% | ||||
| Low | -31.0% | 34.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.